Developmental Therapeutics Research Program

药物治疗学研究：项目总结 弗吉尼亚联邦大学（VCU）梅西癌症中心（MCC）发展治疗学（DT） 该计划的总体目标是利用MCC基础和转化科学来发现，开发和 评估新型MCC构思的小分子和生物制剂在改进癌症策略中的应用 我们的目标是提供更好的治疗方案，并推动MCC努力领导和参与国家和地方的临床试验工作。指导 根据2021 - 2025年MCC战略计划，DT计划的51名成员，代表15个部门和4个部门 VCU学校/学院，领导药物发现和开发，设计合理的药物组合 克服治疗耐药性的方案，并评估最新和最有前途的治疗方法， 通过临床试验。DT成员目前每年持有710万美元的直接同行评审资金 （350万美元来自国家癌症研究所（NCI）; 130万美元来自其他国家卫生研究院; 220万美元来自其他国家卫生研究院。 另外110万美元来自行业和基金会机构。值得注意的是，NCI的资金增加了 与2016年上一次癌症中心支持补助金更新相比，增加了75%。在本项目期间， 在410篇以癌症为重点的研究文章中发表了他们的科学成果， 意见。展示了该计划的高度协作性质，123（30%）出版物是内部的， 154人（38%）与MCC癌症生物学和癌症科学家进行了跨项目研究 预防和控制方案。这些出版物中共有258篇（63%）是与其他出版物合作出版的。 机构，包括其他NCI指定的癌症中心，64（16%）是在高影响（IF> 10）生物医学 科学期刊最重要的是，DT项目的成员与MCC临床试验办公室合作， 该中心的14个疾病工作组与方案审查和监测系统一起， 发起、执行和监督临床试验。2021年，共有153项成人和 儿科患者积极累积（15例由药物启动，91例国家临床试验网络，11例实验性 治疗药物临床试验网络（ETCTN）和36个行业发起的）。自2016年以来，MCC临床研究人员 已经招募了1,000名患者进行治疗试验。作为14个少数民族/服务不足的NCI社区之一， 肿瘤学研究计划指定机构，DT计划在很大程度上有助于MCC的高 少数民族（34%）参与治疗试验。MCC还被邀请通过 玛格丽特公主癌症中心的领导学术组织在2016年，由于其证明 开发和执行早期试验的能力。DT计划中的另一项重要举措是 2018年启动了分子到医学（M2M）计划。具有显著MCC 领导力促进和投资有十几个努力翻译新的代理人发现 和/或由MCC成员跨翻译连续体开发-从目标识别/验证， 通过前期试验的准备阶段。

DEVELOPMENTAL THERAPEUTICS PROGRAM: PROJECT SUMMARY The Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) Developmental Therapeutics (DT) Program’s overarching goals are to leverage MCC basic and translational science to discover, develop, and evaluate novel MCC-conceived small molecules and biologics for application in improved strategies for cancer treatments and to drive MCC’s efforts in leading and participating in national and local clinical trial efforts. Guided by the 2021-2025 MCC Strategic Plan, 51 members of the DT Program, representing 15 departments and four VCU Schools/Colleges, lead efforts in drug discovery and development, designing rational drug combination regimens to overcome therapeutic resistance, and evaluating the very latest and most promising therapeutic approaches through clinical trials. DT members currently hold $7.1M in annual, direct, peer-reviewed funding ($3.5M from National Cancer Institute (NCI); $1.3M from other National Institutes of Health; $2.2M from other agencies) and another $1.1M from industry and foundation agencies. Notably, NCI funding has increased by 75% compared to the last Cancer Center Support Grant renewal in 2016. In the current project period, members have published their scientific results in 410 cancer-focused research articles reporting their discoveries and observations. Demonstrating the program’s highly collaborative nature, 123 (30%) publications were intra- programmatic and 154 (38%) were inter-programmatic with scientists in MCC’s Cancer Biology and Cancer Prevention and Control Programs. In total, 258 (63%) of these publications were in collaboration with other institutions including other NCI-designated cancer centers, and 64 (16%) were in high-impact (IF>10) biomedical science journals. Most importantly, members of the DT Program work with the MCC Clinical Trials Office and the Center’s 14 Disease Working Groups in conjunction with the Protocol Review and Monitoring System to initiate, execute, and monitor clinical trials. In 2021, there were 153 interventional treatment trials for adult and pediatric patients actively accruing (15 investigator-initiated, 91 National Clinical Trials Network, 11 Experimental Therapeutics Clinical Trials Network (ETCTN), and 36 industry-initiated). Since 2016, MCC clinical investigators have enrolled 1,000 patients to treatment trials. Importantly, as one of 14 Minority/Underserved NCI Community Oncology Research Program designated institutions, the DT Program largely contributes to MCC’s high enrollment of minorities (34%) onto treatment trials. The MCC was also invited to join the ETCTN through the Princess Margaret Cancer Center’s Lead Academic Organization in 2016, as a result of its demonstrated capabilities to develop and perform early phase trials. Another important initiative within the DT Program this project period has been the 2018 launch of a Molecules to Medicine (M2M) initiative. With significant MCC leadership facilitation and investment there are more than a dozen efforts to translate novel agents discovered and/or developed by MCC members across the translational continuum – from target identification/validation all the way through the preparatory stages for early phase trials.